SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing extreme volatility as the CME has again raised margin requirements, fueling a heated debate among investors. Bulls contend this is a desperate attempt to suppress prices ahead of anticipated industrial demand and China's impending export restrictions on silver. Conversely, bears view the current action as a "pump and dump," warning of a significant correction similar to past cycles.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending significantly after securing FDA approval for tradipitant, a novel motion sickness drug and the first in nearly 40 years. This approval, coupled with compelling data demonstrating tradipitant's effectiveness in reducing GLP-1 induced nausea and vomiting, has ignited widespread community discussion about its blockbuster potential as an add-on therapy for the rapidly expanding weight-loss drug market. Traders are actively debating potential acquisition interest from major pharmaceutical companies and anticipating substantial upside across VNDA's pipeline.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is buzzing as its community fiercely debates current price stability, with many emphasizing its robust support levels and long-term potential as "digital silver." Despite sentiment around perceived market manipulation, enthusiasts remain confident, highlighting future developments like MWEB privacy and Omnichain integration as key drivers. The widespread call to "buy the dip" underscores a strong conviction for significant future appreciation.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL NASDAQ) is trending due to a fierce debate fueled by year-end tax loss selling and ongoing dilution from early SPAC investors, driving its price downward. The community is deeply split, with proponents viewing current levels as a significant "buy the dip" for a profitable, expanding fintech platform, while critics see a "falling knife" hindered by competition and supply overhang. Many anticipate a rebound in the coming period, drawing parallels to the early trajectories of other major brokerage platforms.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is trending following an eight-figure contract win for spacecraft docking systems and a reiterated "Buy" rating from analysts, fueling bullish sentiment around its role in the expanding space and defense sectors. The community is actively discussing the stock's high short interest, with many anticipating a potential short squeeze, while others remain cautious due to historical dilution concerns. This debate underscores RDW's perceived position as an undervalued player in the burgeoning space infrastructure market.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is experiencing high volatility as investors await an upcoming FDA decision for Relacorilant in Cushing's syndrome, alongside recent positive Phase 3 data for its ovarian cancer treatment. The community is sharply divided, with bullish investors anticipating significant market expansion and a potential short squeeze, while others express caution regarding valuation and regulatory risks. This dynamic biotech remains a focal point for those weighing transformative pipeline potential against immediate market pressures.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending following strong Phase 3 data for its next-generation obesity drug, retatrutide, showing significant weight loss and pain reduction, alongside positive results for oral orforglipron in weight maintenance. This solidifies investor confidence in its dominant GLP-1 pipeline, even as the community discusses potential acquisitions and its ongoing competition in the rapidly expanding weight-loss market.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending with exceptionally high trading volume following news of a proposed business combination with Applied Digital's cloud division to form the AI compute platform ChronoScale. The community is actively debating the implications of this AI-focused pivot, with discussions centered on its low float, potential for a short squeeze, and the significant gains already seen. While many anticipate further upside, some express caution regarding the long-term value for current shareholders due to potential dilution from the deal.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers is a trending topic following its S&P 500 inclusion and a strong Q3 earnings beat, which showcased robust client growth and trading activity. Despite numerous analyst upgrades and a bullish long-term outlook for its tech-led global expansion, community discussion reflects mixed reactions to the stock's immediate price performance, often contrasting it with competitors in the evolving brokerage landscape.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

AGNC Investment Corp. is trending amid widespread anticipation of future interest rate cuts, a catalyst broadly perceived as bullish for the mREIT sector. The community is actively discussing the stock's consistent high monthly dividend and expresses confidence in its potential for both price appreciation and stable income, with many noting its perceived resilience in a volatile market despite some technical indicators suggesting overbought conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vincerx Pharma ($VINC) shares were in the spotlight over the weekend following the company’s proposed merger with Oqory, a privately-held, clinical-stage company that develops ADCs for the treatment of multiple oncology conditions, with retail sentiment staying strong.Vincerx stock was up 64% in after-hours trading session on Friday.Upon completion of the proposed merger, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%.Vincerx plans to reduce its workforce and undertake cost-control measures, the company said. As part of this workforce reduction, its CEO Dr. Ahmed Hamdy has stepped down but will remain as chairman. Dr. Raquel Izumi has stepped down as president and COO and taken over as acting CEO in a consulting capacity; Alexander Seelenberger has stepped down as CFO.Retail sentiment on Stocktwits has remained ‘bullish’ on the stock. Message volumes are in the ‘normal’ zone.<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_10_18_33_AM_bd88e280b0.png" alt="Screenshot 2024-12-30 at 10.18.33 AM.png" width="1256" height="302"><figcaption>VINC sentiment meter and message volumes on Dec 29 as of 11:45 pm ET</figcaption></figure><stembedurl>https://stocktwits.com/jlemx/message/598101092</stembedurl>The merger is subject to customary closing conditions and the completion of the minimum $20 million in financing, and the continued listing of Vincerx's common stock on Nasdaq.According to a Vincerx statement, the transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders.Additionally, certain Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches.The financing consists of about $1 million funded through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 funded on or prior to January 31, 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish

 Retail sentiment on Stocktwits has remained ‘bullish’ on the stock. 

Equity

Shares of Vincerx Pharma saw volatile trading on Wednesday, swinging between gains and losses after the company unveiled significant cost-cutting measures.&nbsp;The moves are aimed at advancing its VIP943 program, a cancer treatment for leukemias and myelodysplastic syndrome, the company said.Vincerx CEO Ahmed Hamdy reiterated the company’s commitment to VIP943, highlighting positive early results from the Phase 1 dose-escalation study.&nbsp;The trial showed promising safety and efficacy, with a relapsed AML patient achieving complete remission with incomplete blood count recovery (CRi) and a higher-risk MDS patient achieving complete remission with leukemic cells (CRL).&nbsp;Notably, the CRi patient showed significant improvement, with their bone marrow revealing only 1% cancer cells after seven months.To ensure the continued development of VIP943, Vincerx is taking aggressive steps to streamline operations and focus resources on the trial’s advancement.&nbsp;That includes a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.&nbsp;The company also announced plans to engage a financial advisor to guide the strategic review process.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VINC_sentiment_and_message_volume_Dec_4_196f59dc07.png" alt="VINC sentiment and message volume Dec 4 .png" width="1318" height="318"><figcaption>VINC sentiment and message volume Dec 4 as of 10:45 am ET | source: Stocktwits</figcaption></figure>Retail activity surrounding VINC surged, with message volume on Stocktwits reaching the second-highest level in the past year, while sentiment remained ‘bullish’.&nbsp;One watcher speculated that a reverse stock split or partnership deal could be in the works.<stembedurl>https://stocktwits.com/HoHoHoHum/message/594996367</stembedurl><a href="https://stocktwits.com/symbol/VINC">Vincerx’s stock</a> has struggled, losing over 75% of its value year-to-date.&nbsp;As of Oct. 31, the company had $8.4 million in cash and is actively pursuing partnerships to advance other oncology treatments, including VIP236 for solid tumors and enitociclib for leukemia.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail activity surrounding VINC surged, with message volume on Stocktwits reaching the second-highest level in the past year.

Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials 

The company's plans include a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.

VINC
Vincerx Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VINC News

VINCVincerx Pharma Inc